Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAV680 and Cetirizine in Allergic Rhinitis
NCT01103050Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Jul 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QAV680 in allergic rhinitis (AR) (4 arms), sponsored by Novartis. Primary endpoint: Total Nasal Symptom Score at 14 days. Started Mar 2010; status: completed.
02
Drugs
QAV680
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01103050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103050.